1. Apolipoprotein A-IV concentrations and clinical outcomes in chronic kidney disease patients: Results from the German Chronic Kidney Disease (GCKD) study. (August 2021) Authors: Schwaiger, J.P.; Kollerits, B.; Steinbrenner, I.; Weissensteiner, H.; Schönherr, S.; Forer, L.; Kotsis, F.; Schneider, M.P.; Schultheiss, U.T.; Wanner, C.; Köttgen, A.; Eckardt, K.-U.; Kronenberg, F. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Statin treatment and prevalent CVD influence the association between PCSK9 and incident CVD in patients with moderately decreased kidney function: Results from the GCKD study. (August 2022) Authors: Kheirkhah, A.; Lamina, C.; Kollerits, B.; Schachtl-Riess, J.F.; Schultheiss, U.T.; Forer, L.; Sekula, P.; Kotsis, F.; Köttgen, A.; Eckardt, K.U.; Kronenberg, F. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Strong association between serum PCSK9 and cardiovascular disease in patients with moderate chronic kidney diseases - The GCKD study. (August 2021) Authors: Kheirkhah, A.; Lamina, C.; Kollerits, B.; Schachtl-Riess, J.F.; Schultheiss, U.T.; Forer, L.; Sekula, P.; Kotsis, F.; Köttgen, A.; Eckardt, K.-U.; Kronenberg, F. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗